See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Products
GBI Health Data Intelligence Suite
Solutions
Full Life-Cycle Solutions for Pharmaceuticals
Powered by global drug pipeline data, the Competitive Landscape Analysis solution enables multidimensional analysis across drugs, targets, indications, and technologies. It helps R&D teams identify strategic opportunities, prioritize investments, and make more informed development decisions.
Drawing on data from six major global clinical trial registries, the Clinical R&D Insights solution provides deep visibility into global trial activity and protocol designs, helping teams optimize clinical development strategies and trial execution.
Drawing on data covering the National Reimbursement Drug List (NRDL), public procurement and tendering, Huiminbao (commercial health insurance), Patient Assistance Programs (PAPs), and healthcare policies and regulations, the Market Access Strategy solution supports market access planning, pricing analysis, and regional opportunity assessment to accelerate commercialization and market access.
Built on comprehensive researcher profiles, the GBI KOL/HCP Management solution enables researcher identification, segmentation, academic influence analysis, and collaboration network mapping, helping Medical Affairs, Marketing, and Sales teams improve researcher engagement and operational efficiency.
Industry News and Reports
Aggregating industry news and in-depth reports to help pharma companies stay ahead.
- Sanofi's BTKi rilzabrutinib approved in China
On September 9, 2026, Sanofi announced that rilzabrutinib received approval from China's National Medical Products Administration (NMPA) for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to prior therapies such as corticosteroids or immunoglobulins, or in whom these treatments are poorly tolerated.
- Transcenta announces HiCB Platform collaboration with WuXi Biologics
On September 9, 2026, Transcenta Holding (06628.HK) announced that it has entered into a technology license and strategic collaboration agreement with WuXi Biologics.
- BD (Tianjin) Life Health Innovation Center Officially Opens
On September 5, 2026, the BD (Tianjin) Life Health Innovation Center officially opened its doors, with seven BD clinical training centers inaugurated on the same day.
- Baiyunshan’s rabies vaccine approved in Macau, China
On September 8, 2026, Guangzhou Baiyunshan Pharmaceutical Co., Ltd. (Baiyunshan, 600332.SH) announced that its freeze-dried rabies vaccine (Vero cells) for human use has been officially approved for registration and marketing in Macau, China.
- Ascletis initiates Phase 1 study of oral anti-obesity drug ASC36 in US
On September 8, 2026, Ascletis Pharma (1672.HK) announced the initiation of a US Phase 1 study of ASC36 oral tablets (oral amylin receptor agonist) for the treatment of obesity.
- China issues 5-year work plan to enhance eye health services
On September 7, 2026, China's National Health Commission (NHC) issued the Work Plan to Accelerate the Provision of High-Quality and Efficient Eye Health Services (2026–2030), setting forth the following major targets to be achieved by 2030: ① Steady improvement in the refractive screening rate for children aged 0–6 years and primary and secondary school students; growing awareness among the elderly regarding scientific correction of refractive errors; and continuous increase in the Effective Refractive Error Coverage (eREC).
In-Depth, Exclusive Industry Reports
Curated by expert analysts, offering in-depth analysis of emerging industry trends and the competitive landscape.
Scan the QR code to follow the GBIHealth WeChat Official Account for industry news, live webinars, thematic reports, and more.
Reliable partner for 95%+ key global medical industry players
Our clients are drawn from across pharma, medical device firms, CROs/CDMOs, investors, consulting firms, and others
See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us